Leveraging Pharma.AI for Neuroimmune Research
Insilico and SK Biopharm Partner in $2.5B AI Drug Deal
Companies aim to discover novel treatments for neuroimmune and central nervous system disorders using AI platforms.
A high-tech laboratory environment showing digital displays of complex molecular structures and pharmaceutical data.
Photo: Avantgarde News
Insilico Medicine and SK Biopharmaceuticals announced a strategic research and development partnership to discover drug candidates for neuroimmune disorders [1]. The collaboration is valued at up to $2.5 billion [1][2]. The project will focus on targeting central nervous system diseases using advanced artificial intelligence [1][3].
The deal utilizes Insilico’s Pharma.AI platform alongside the clinical development expertise of SK Biopharmaceuticals [1]. While the total value is high, reports indicate the deal is heavily backloaded with milestone payments [2]. Both companies aim to accelerate the discovery of novel treatments for complex medical conditions [3].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
prnewswire.com
https://www.prnewswire.com/news-releases/insilico-medicine-and-sk-biopharmaceuticals-achieved-ai-powered-drug-discovery-collaboration-worth-up-to-2-5-billion-for-neuroimmune-disorders-302806072.html
- 2.↗
fiercebiotech.com
https://www.fiercebiotech.com/biotech/insilico-lands-heavily-backloaded-25b-ai-drug-discovery-deal-sk-biopharm
- 3.↗
techinasia.com
https://www.techinasia.com/news/sk-biopharma-taps-insilico-for-2-5b-ai-drug-deal
Related stories
View all
Topics
About the author
Avantgarde News Desk covers leveraging pharma.ai for neuroimmune research and editorial analysis for Avantgarde News.